MCMolly M. Crenshaw

Molly M. Crenshaw

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Molly M. Crenshaw has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Areeg El-Gharbawy

    Division of Medical Genetics, Department of Pediatrics Duke University Medical Center Durham North Carolina USA

    2 shared publications
  • Daniel G. Piqué

    University of Colorado School of Medicine (CU-SOM), Department of Pediatrics, Section of Genetics and Metabolism, Aurora, Colorado, USA

    2 shared publications
  • Margarita Saenz

    Department of Pediatrics, Section of Genetics and Metabolism University of Colorado School of Medicine (CU‐SOM) Aurora Colorado USA

    2 shared publications
  • A. Larson

    Department of Pediatrics, Section of Clinical Genetics and Metabolism University of Colorado School of Medicine Aurora Colorado USA

    1 shared publication
  • Aaina Kochhar

    Section of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO

    1 shared publication
  • Ana Sueli Rodrigues Cavalcante

    Department of Bioscience and Oral Diagnosis, School of Dentistry of São José dos Campos, São Paulo State University, São José dos Campos, São Paulo, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Early Detection in Action: Developing and Refining Newborn Screening for Pompe Disease in North Carolina

    by Molly M. Crenshaw, Erica Burner-Nading, Jamie Mills, Erin Huggins, Natalie Krohl, Bali Deeksha, Sarah Young, Ashlee R. Stiles, Kimberly Blake, Lara Percenti, et al.

    Pompe disease, a lysosomal disease, was added to the Recommended Uniform Screening Panel in 2015, and it has been included in the newborn screening (NBS) panel in North Carolina (NC) since February 2023. Across the world, the approach to NBS for Pompe disease varies. This study adds to the literature 20 months of population level health data from NC regarding infants who screened positive for Pompe disease via NBS. Fifty-two of 228,474 (0.02%) infants screened positive for Pompe disease, and after diagnostic testing, 18 (35%) were diagnosed with presumed late-onset Pompe disease (LOPD), resulting in a higher than previously reported incidence of 1 in 12,693. No infants with the infantile onset form of disease were identified at the time of data closure. While seasonal variations existed in the absolute value of dried blood spot (DBS) acid α-glucosidase (GAA) enzyme activity, this was successfully controlled for using cutoffs defined by the percent of the daily median of enzyme activity. None of the following parameters correlated with the final clinical designation in a statistically significant manner: percent of the daily median DBS GAA enzyme activity, creatine/creatinine/GAA ratio, nor birthweight. The use of the creatine/creatinine/GAA ratio has been eliminated in NC because of these data. The GAA/α-L-iduronidase ratio was statistically significant in its association to final clinical designations of Pompe disease, and thus provides an opportunity to further refine NBS for Pompe disease in NC. The mean GAA enzyme activity was also statistically significantly different based on the age of NBS sample collection. We propose two algorithms that outline 1) an approach to enable timely treatment of the infantile onset form of Pompe disease; and 2) a more detailed approach for reaching a clinical designation after a positive NBS for Pompe disease. Opportunities for growth, remaining questions, and responsible stewardship of our public health resources are discussed.

  • Open Access

    Hypoaminoacidemia and Pyroglutamic Aciduria: Potential Biomarkers in Malnutrition‐Related Hyperammonemia

    by M. M. Crenshaw, O. M. D'ANnibale, V. Martucci, S. Gracie, A. Kochhar, J. Stansauk, A. Larson, P. Baker, C. Peck, T. Wood, et al.

    Hyperammonemia is a medical emergency, and the cause must be identified quickly in order to treat appropriately. Malnutrition is a known risk factor for hyperammonemia; however, there are limited reliable lab indicators used to identify malnutrition. Early identification of the etiology of hyperammonemia is crucial to optimizing care, specifically reintroduction of appropriate amounts of protein into the diet. Herein, we discuss three patients with complex medical histories and clinical signs of malnutrition who presented with hyperammonemia. In all three patients, both hypoaminoacidemia and pyroglutamic aciduria were observed. Specifically, all patients had low tyrosine, tryptophan, methionine, and branched‐chain amino acids. Recognizing this biochemical pattern could result in more rapid initiation of supplementing protein, a primary tenet of treatment in malnutrition‐related hyperammonemia. We highlight the unique features of malnutrition‐related hyperammonemia, propose mechanisms to explain the pattern, and suggest a framework for managing these cases.

  • Open Access

    Treatable Neonatal Molybdenum Cofactor Deficiency: Rapid Demise Despite Rapid Biochemical Diagnosis

    by Molly M. Crenshaw, Yasmeen Midgette, Shruthi Mohan, Ruhan Wei, Mariele Anneling, Monika Williams, Milap Patel, Benjamin T. Cocanougher, Sarah P. Young, Dmitriy Niyazov, et al.

    Molybdenum cofactor deficiency (MoCD) is an inborn error of metabolism included in the differential for refractory neonatal seizures. The prognosis is guarded, with a median reported age of death between 2.4 and 3.0 years. Mortality is primarily due to seizures and lower respiratory tract infections. MoCD has a distinct biochemical profile, characterized by elevated urinary S ‐sulfocysteine, xanthine, and hypoxanthine, and low or undetectable serum and urine uric acid levels. A disease‐altering treatment is available for MoCD Type A; however, due to the rarity of the condition, its natural history remains poorly understood. We present a patient with neonatal‐onset refractory seizures, whose biochemical testing, performed within 24 h of specimen receipt in the laboratory, revealed a pattern consistent with MoCD. Before the genetics team could disclose the preliminary diagnosis, the patient demised, without evidence of worsening seizures or respiratory infection. Results of genome sequencing, guided by biochemical findings, identified double homozygous pathogenic variants in MOCS1 (associated with MoCD Type A). Although the biochemical genetics laboratory's protocol for analyzing and reporting S ‐sulfocysteine levels within 48 h enabled a rapid preliminary diagnosis, the patient's condition deteriorated too quickly to initiate disease‐altering treatment, progressing more rapidly than described in the literature. We discuss potential hypotheses for his rapid decline and the broader implications for the field of biochemical genetics.


  • The Trusted Senior: How Attendings and Residents Can Co‐Create Success

    by Molly M. Crenshaw, Joanne Alfred, Cheryl Yang, Lauren R. Anderson

    Growth mindset, the belief that one's abilities are changeable, is a valued attribute in medical education. Developing a growth mindset is also in direct tension with systems that evaluate performance, such as in medical training. The senior resident role is a microcosm of this tension because it is a pivotal transition time from training to attending. A recently updated framework for clinical competency places trusted as the highest goal for trainees, defined as self‐awareness that is bolstered by humility, integrity, and reliability. We provide strategies for both the senior and attending to foster a senior's goal of trusted status. This requires intentional work by both the senior and attending, but we posit that the attending role is paramount in first creating a learning environment that celebrates a growth mindset. The strategies work to promote self‐reflection, active problem solving, and exploration of the gray areas of medical decision making to maximize the learning experience.


  • Open Access

    An Atypical 15q11.2 Microdeletion Not Involving SNORD116 Resulting in Prader–Willi Syndrome

    by Molly M. Crenshaw, Sharon L. Graw, Dobromir Slavov, Theresa A. Boyle, Daniel G. Piqué, Matthew Taylor, Peter Baker

    Loss of expression of paternally imprinted genes in the 15q11.2-q13 chromosomal region leads to the neurodevelopmental disorder PraderWilli Syndrome (PWS). The PWS critical region contains four paternally expressed protein-coding genes along with small nucleolar RNA (snoRNA) genes under the control of the SNURF-SNRPN promoter, including the SNORD116 snoRNA gene cluster that is implicated in the PWS disease etiology. A 5-7Mb deletion, maternal uniparental disomy, or an imprinting defect of chromosome 15q affect multiple genes in the PWS critical region, causing PWS. However, the individual contributions of these genes to the PWS phenotype remain elusive. Reports of smaller, atypical deletions may refine the boundaries of the PWS critical region or suggest additional disease-causing mechanisms. We describe an adult female with a classic PWS phenotype due to a 78kb microdeletion that includes only exons 2 and 3 of SNURF-SNRPN with apparently preserved expression of SNORD116.


  • Congenital diaphragmatic hernia in siblings with PIGA‐related congenital disorder of glycosylation

    by Molly M. Crenshaw, Lauren Thompson, Daniel G. Piqué, Kestutis Micke, Margarita Saenz, Peter R. Baker

    There are over 150 proteins involved in glycosylphosphatidylinositol (GPI)-anchored protein biosynthesis, a class within the larger category of congenital disorders of glycosylation (CDG). Pathogenic variants identified in phosphatidylinositol glycan class A protein (PIGA) are associated with X-linked PIGA-CDG, a GPI-anchor defect. The disease has primarily been characterized by hypotonia, epilepsy, and global developmental delay; however, only 89 known cases are reported, so the phenotypic spectrum has likely not yet been fully delineated. Congenital diaphragmatic hernia (CDH) has been reported in patients with various GPI-anchor related defects but has only been described in one prior individual with PIGA-CDG. Here, we describe the second and third reported cases of CDH in two brothers with PIGA-CDG caused by a pathogenic missense variant in PIGA: c.355C > T, p.R119W. Chromosomal microarray and whole exome sequencing did not reveal another plausible explanation for the CDH. We relate our patients' clinical features to the single previously reported individual with CDH and PIGA-CDG. We then compare this case series with the subset of individuals with CDH and other GPI-anchor defects. These findings suggest that CDH should be considered in the phenotypic disease spectrum of PIGA-CDG.


  • Five siblings expand the spectrum of GPC6‐related skeletal dysplasia

    by Molly M. Crenshaw, Mariana L. Meyers, Kathleen Brown, Valerie Slegesky, Jessica Duis, Ellen R. Elias, Margarita Saenz, Wen Shi, Jorge Filmus, Naomi J. L. Meeks

    Skeletal dysplasias broadly include disorders of cartilage or bone. Omodysplasia‐1 is a type of skeletal dysplasia caused by biallelic loss of function variants in the GPC6 gene. GPC6 codes for the protein glypican 6 (GPC6) (OMIM *604404), which stimulates bone growth. We report a family in which five out of nine children were presented with a skeletal dysplasia characterized phenotypically by mild short stature and rhizomelia. All affected individuals were found to have homozygous missense variants in GPC6: c.511 C>T (p.Arg171Trp). Radiograph findings included rhizomelic foreshortening of all four extremities, coxa breva, and ulna minus deformity. Using a Hedgehog (Hh) reporter assay, we demonstrate that the variant found in this family results in significantly reduced stimulation of Hh activity when compared to the wild‐type GPC6 protein, however protein function is still present. Thus, the milder phenotype seen in the family presented is hypothesized due to decreased GPC6 protein activity versus complete loss of function as seen in omodysplasia‐1. Given the unique phenotype and molecular mechanism, we propose that this family's findings widen the phenotypic spectrum of GPC6‐related skeletal dysplasias.


  • Open Access

    Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum

    by Ioannis G. Koutlas, Ana-Lia Anbinder, Rana Alshagroud, Ana Sueli Rodrigues Cavalcante, Mohammed Al Kindi, Molly M. Crenshaw, Julie C. Sapp, Hannah Kondolf, Marjorie J. Lindhurst, Jeffrey N. Dudley, et al.